Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Significance: NEPC is a highly aggressive subtype of prostate cancer that is increasing in incidence, likely due to use of new secondary androgen deprivation therapies. Here, we demonstrate that Trop2 is significantly elevated in CRPC and NEPC and represents a driver of metastatic NEPC. Trop2 overexpression increases tumor growth, drives metastasis and neuroendocrine phenotype, and significantly increases PARP1 levels. Inhibition of PARP1 in Trop2-driven NEPC significantly decreases neuroendocrine features, tumor growth, and metastatic colonization in vivo, suggesting that PARP1 inhibitors may represent a promising therapeutic strategy for metastatic prostate cancer expressing high levels of Trop2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1. Trop2 is elevated in prostate cancer and positively associated with biochemical recurrence and metastatic risk. (A) IHC staining of Trop2 on tissue microarrays (TMAs) composed of normal prostate (n = 26) and prostate cancer Gleason 4+3 (n = 79). Trop2 staining intensity was scored from 0 to 3 (0 is negative, 1 is uninterpretable, 2 is weak positive [low], 3 is strong positive [high]). Representative images for negative and high staining are shown. (Scale bars represent 200 and 25 μm, respectively [enlarged images].) Examples for negative, low, and high Trop2 staining are shown in SI Appendix, Fig. S1. (Right) Represents the distribution of Trop2 intensity scores as a percentage of patient samples. (B) Trop2 IHC on independent TMAs with associated clinical and pathological data. Representative images for Trop2 staining of patient samples with different Gleason scores and recurrence status are shown. (Scale bars represent 200 and 25 μm, respectively [enlarged images in Lower].) (C) Strong staining for Trop2 correlates with prostate cancer recurrence after prostatectomy (recurrent patients, n = 58, and nonrecurrent patients, n = 176). P = 0.01 by log-rank test. (D) Strong Trop2 expression correlates with prostate cancer metastasis. Samples from patients with no metastasis (Non-met) (n = 204) and patients with metastasis (n = 18, including lymph node [LN] [n = 12] and bone metastasis [n = 6]) were used. The statistical significance of the differences between no metastasis and metastasis proportions was calculated by the normal distribution N(0,1) of the z-score. P = 0.02.](https://figures.cochat.ai/paper-figures/cf29ef2d77604e7e959234b671915d9f/trop2-is-a-driver-of-metastatic-prostate-cancer-with-neuroendocrine-phenotype-figure-1.jpg)

![Fig. 3. Trop2 regulates migration and invasion in vitro. (A) Transwell chamber assays to assess migration after 20 h incubation of DU145-RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells. Experiments were performed in triplicate, and three images per well were used to quantify stained cells that had migrated. The average number of cells in nine fields (three wells) and percentage of migration were normalized to the DU145-RFP cell counts. One of three independent experiments is shown. (Scale bars: 100 μm.) (B) Wound healing assays for DU145- RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells. Experiments were performed in triplicate, and 10 images were acquired per well at 0, 12, 24, and 36 h. The average of the wound area in three wells at 0 h was assigned 100% and used to quantify changes in wound area over time. Representative images are shown. (Scale bar: 100 μm.) (C) Boyden chamber assays to assess invasion of DU145-RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells into a Matrigel-coated insert membrane after 20 h. Representative experiment. (Scale bar: 100 μm.) (D) Matrigel drop 3D invasion assay using LNCaP-RFP and LNCaP-Trop2-OV cells with control shRNA (shControl) or Trop2 shRNA (shTrop2). Cancer cells (5 × 104) in Matrigel were seeded in a 24-well plate, and drops were imaged at day 0 and day 6 using Celigo imager. The cell migration area outside of the drop was measured. Experiments were performed in triplicate, and the relative invasion ability of cancer cells was normalized to the Trop2-OV group. Orange pseudocolor represents living cells from RFP fluorescent signal of stable clones. (Scale bars: 1 mm and 500 μm [enlarged images].) Error bars represent SD. **P < 0.01 and ***P < 0.005 by Student’s t test.](https://figures.cochat.ai/paper-figures/37a0d158126c4e6f880a10c8ed3c10c0/trop2-is-a-driver-of-metastatic-prostate-cancer-with-neuroendocrine-phenotype-figure-3.jpg)
![Fig. 4. Trop2 drives bone and liver metastasis in vivo. (A) LNCaP-RFP and LNCaP-Trop2-OV cells (1 × 105) expressing luciferase and RFP were injected into the left ventricle of male NSG mice (n = 11 and n = 9). Whole body bioluminescence intensity (BLI) (photons/second/cm2/surface radiance) is shown and quantified at day 21 in Right. Red circles 1 and 2 show the tibiae of experimental animals displayed in B and C. (B) Tibiae metastases were imaged by μCT and reconstructed using maximum-intensity projection (MIP) and volume rendered (VR-3D) 3D techniques. Yellow arrows indicate tumor lesions. (Scale bars of μCT images: 500 μm and 50 μm [enlarged images].) (C) RFP signal representing tibial bone metastasis of LNCaP-Trop2-OV cells (yellow arrowheads). Tibiae and livers were also imaged with dark-field (DF) application in C, D, G, and H. The percentage of mice with bone metastasis is shown in the Right. IHC of bone metastases demonstrates expression of human Trop2. B.M., bone marrow. (Scale bar: 2 mm.) (D) RFP signal of the liver surface for LNCaP-RFP and RFP-labeled LNCaP-Trop2-OV. IHC for human Trop2 is shown in the Middle. (Scale bars: 1 mm, low power, and 250 μm, high power images.) Number and size of liver metastases based on counting of the RFP foci using ImageJ are shown at Right. (E) Bioluminescence activity 21 d after intracardiac injection of 1 × 105 luciferase-labeled DU145-RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells in male NSG mice (n = 5 to 6). Red circles 3, 4, and 5 indicate the tibiae of the same experimental animals displayed in F and G. BLI is shown graphically on the Right. (F) Volume rendered μCT images of tibial lesions (indicated by the yellow arrows) of the DU145-derived cell lines. (Scale bars of μCT images: 500 μm and 50 μm [enlarged images].) (G) Fluorescence microscopy of harvested hind limbs for RFP demonstrating bone metastases indicated by the yellow arrowheads. (Scale bars: 2 mm.) The percentage of mice with bone metastasis is quantified in the Right. (H) Liver lesions in the DU145-derived cell lines displayed in D imaged for surface RFP expression, and sliced FFPE tissues stained for hTrop2 IHC. Number of metastatic foci and size of foci quantified in Right. Error bars depict SEM. (Scale bars: 1 mm, low power, and 250 μm, high power images.) *P < 0.05, **P < 0.01, ***P < 0.005; n.s., not significant.](https://figures.cochat.ai/paper-figures/e738799e4daa44588a5b693dc9cecf06/trop2-is-a-driver-of-metastatic-prostate-cancer-with-neuroendocrine-phenotype-figure-4.jpg)


![Fig. 7. Targeting PARP1 enzyme activity in Trop2-driven NEPC suppresses tumor growth, bone metastasis, and reverses Trop2-induced NEPC phenotype. (A) Western blot of Trop2 and PARP1 proteins in LNCaP-RFP and LNCaP-Trop2-OV. (B) Immunocytochemistry and confocal imaging for Trop2, and PARP1 enzyme activity (PARylation) in paraformaldehyde-fixed LNCaP-RFP and LNCaP-Trop2-OV cells treated with DMSO control, talazoparib (10 nM) or olaparib (10 μM) for 3 d. (Scale bars: 10 μm.) (C) Colony formation assays of LNCaP-RFP or LNCaP-Trop2-OV cells treated with talazoparib (0–25 nM) or olaparib (0–5 µM). At day 9, the colonies were fixed and stained with crystal violet, and the percentage of colony area per well is plotted as percent colony formation relative to the Trop2-OV treated with vehicle. (D) Growth of LNCaP-Trop2-OV s.c. xenografts treated daily with talazoparib (0.5 mg/kg) or olaparib (50 mg/kg), injected i.p. (tumor n = 7 to 11 per experimental group). (E) IHC staining for Trop2, PARP1, and PARP1 enzyme activity (PARylation), and three neuroendocrine markers (CD56, SYP, and CHGA) in LNCaP-Trop2-OV tumor xenografts treated with vehicle (veh), talazoparib (Tala) or olaparib (Ola) or LNCaP-RFP control with vehicle or olaparib. (Scale bars: 50 μm.) (F) Matrigel drop invasion assays of LNCaP-RFP or LNCaP-Trop2-OV cells treated with talazoparib or olaparib. Representative images of invading edge of the whole Matrigel drop (Upper) and enlarged image (Lower) are shown. The percentage of relative invading area per drop is shown in the Right Graph. (Scale bars: 1 mm [Upper] and 200 μm [Lower].) (G) Olaparib decreases metastasis of LNCaP-Trop2-OV cells in an intracardiac injection model. Olaparib (50 mg/kg) or vehicle control began 3 d after intracardiac injection with imaging at 7 and 14 d (see Insert of study design). BLI of mice at day 0 and day 14 of control (Ctl) and olaparib-treated animals is shown at Left, and whole body quantified BLI is shown at the Bottom Right. Percentage of mice with tibial bone metastasis in control and olaparib-treated mice is shown at Bottom Right. Error bars represent SD, and in vivo panels error bar = SEM. *P value < 0.05, **P value < 0.01, and ***P value < 0.005, assessed by Student’s t test.](https://figures.cochat.ai/paper-figures/607b189e104b4735bcdc510bb4c6b42e/trop2-is-a-driver-of-metastatic-prostate-cancer-with-neuroendocrine-phenotype-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Trop2 promotes prostate cancer growth, metastasis, and treatment resistance, and its expression is associated with inferior outcomes123–125.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [124]
The cited source says what the claim attributes to it.
In the citing paper
“Trop2 may also play a role in the neuroendocrine differentiation phenotype, a well-characterized mechanism for ADT-resistance in prostate tumors123,124.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw937 · Cited by 6,980
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationDNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Ray Chaudhuri, A., & Nussenzweig, A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.53 · Cited by 1,786
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B. V. S. K., Varambally, S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4045 · Cited by 1,685
Ku, S. Y., Rosario, S., Wang, Y., Mu, P., Seshadri, M., Goodrich, Z. W., Goodrich, M. M., Labbé, D. P., Gomez, E. C., Wang, J., et al. (2017) · Science · doi:10.1126/science.aah4199 · Cited by 1,089
Nuclear structure in cancer cells
Zink, D., Fischer, A. H., & Nickerson, J. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1430 · Cited by 1,068
Mu, P., Zhang, Z., Benelli, M., Karthaus, W. R., Hoover, E., Chen, C.-C., Wongvipat, J., Ku, S.-Y., Gao, D., Cao, Z., et al. (2017) · Science · doi:10.1126/science.aah4307 · Cited by 1,050
Cited by
A proteogenomic portrait of lung squamous cell carcinoma
Satpathy, S., Krug, K., Jean Beltran, P. M., Savage, S. R., Petralia, F., Kumar-Sinha, C., Dou, Y., Reva, B., Kane, M. H., Avanessian, S. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.016 · Cited by 377
Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer
Ghoochani, A., Hsu, E.-C., Aslan, M., Rice, M. A., Nguyen, H. M., Brooks, J. D., Corey, E., Paulmurugan, R., & Stoyanova, T. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3477 · Cited by 306
Self-citationPance, K., Gramespacher, J. A., Byrnes, J. R., Salangsang, F., Serrano, J.-A. C., Cotton, A. D., Steri, V., & Wells, J. A. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01456-2 · Cited by 265
Trop2: Jack of All Trades, Master of None
Lénart, S., Lenárt, P., Šmarda, J., Remšík, J., Souček, K., & Beneš, P. (2020) · Cancers · doi:10.3390/cancers12113328 · Cited by 154
Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer
Liu, X., Deng, J., Yuan, Y., Chen, W., Sun, W., Wang, Y., Huang, H., Liang, B., Ming, T., Wen, J., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108296 · Cited by 124
Metadata
- Authors
- Hsu, E.-C., Rice, M. A., Bermudez, A., Marques, F. J. G., Aslan, M., Liu, S., Ghoochani, A., Zhang, C. A., Chen, Y.-S., Zlitni, A., Kumar, S., Nolley, R., Habte, F., Shen, M., Koul, K., Peehl, D. M., Zoubeidi, A., Gambhir, S. S., Kunder, C. A., Pitteri, S. J., Brooks, J. D., & Stoyanova, T.
- Affiliations
- Stanford Medicine (US)
- Department of Radiology, Stanford University, Stanford, CA 94304;
- University of British Columbia (CA)
- University of California, San Francisco (US)
- Corresponding author
- Stoyanova, Tanya
- ORCID
- Hsu, En-Chi
- Rice, Meghan A.
- Bermudez, Abel
- Marques, Fernando Jose Garcia
- Aslan, Merve
- Liu, Shiqin
- Ghoochani, Ali
- Zhang, Chiyuan Amy
- Chen, Yun-Sheng
- Zlitni, Aimen
- Kumar, Sahil
- Nolley, Rosalie
- Habte, Frezghi
- Shen, Michelle
- Peehl, Donna M.
- Zoubeidi, Amina
- Gambhir, Sanjiv S.
- Kunder, Christian A.
- Pitteri, Sharon J.
- Brooks, James D.
- Stoyanova, Tanya
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2020-01-13
- Volume
- 117
- Issue
- 4
- Pages
- 2032-2042
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6994991
- OpenAlex
- W2999659032
- Cited by
- 146
- References
- 46
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 19 · 2023: 28 · 2022: 30 · 2021: 25 · 2020: 8
- FWCI
- 12.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Funders
- NIH (R03CA230819)
- DOD PCRP (W81XWH1810323, W81XWH1810141)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- TROP2, neuroendocrine prostate cancer, castration-resistant prostate cancer, PARP1, PARP inhibitors, metastasis, androgen deprivation therapy resistance, tumor recurrence, therapeutic target, tumor growth
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, Animals, Antigens, Neoplasm, Bone Neoplasms, Cell Movement, Follow-Up Studies, Humans, Male, Neoplasm Invasiveness, Phenotype, Prognosis, Tumor Cells, Cultured, Biomarkers, Tumor, Cell Adhesion Molecules, Gene Expression Regulation, Neoplastic, Survival Rate, Mice, SCID, Mice, Inbred NOD, Apoptosis, Carcinoma, Neuroendocrine, Xenograft Model Antitumor Assays, Cell Proliferation, Mice, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. https://app.cochat.ai/papers/10.1073/pnas.1905384117
- The paper
- Hsu, E.-C., Rice, M. A., Bermudez, A., Marques, F. J. G., Aslan, M., Liu, S., Ghoochani, A., Zhang, C. A., Chen, Y.-S., Zlitni, A., Kumar, S., Nolley, R., Habte, F., Shen, M., Koul, K., Peehl, D. M., Zoubeidi, A., Gambhir, S. S., Kunder, C. A., . . . Stoyanova, T. (2020). Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1905384117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.